心力衰竭中的疾病修饰疗法:最新情况
1Department of Cardiovascular Medicine, Saga University, Saga, Japan.
QJM : monthly journal of the Association of Physicians
|March 4, 2025
概括
对心力衰竭的药理疗法选择,轻微减少/保留喷射分数 (HFmrEF/HFpEF) 是有限的. 最近的试验表明,新的药物,如finerenone和GLP-1受体激动剂可能为这一群体提供有效的治疗策略.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 有限的基于证据的疾病修饰药物疗法存在于心力衰竭中,轻微减少/保留射出分数 (HFmrEF/HFpEF).
- 这代表了当前心力衰竭管理中的重大未满足的临床需求.
- 现有的治疗方法主要集中在症状管理上,而不是解决该队列的潜在疾病进展.
研究的目的:
- 讨论新兴药物治疗方法在治疗HFmrEF/HFpEF方面的潜在作用.
- 根据最近的临床试验结果,为患有HFmrEF/HFpEF的患者提出更新的药理策略.
- 为解决未满足的临床需要,有效的疾病修饰治疗在这个患者群体.
主要方法:
- 对特定药物的最近临床试验数据的审查.
- 在HFmrEF/HFpEF群体中分析芬和葡萄糖类-1受体激动剂的疗效和安全性.
- 综合证据,制定一个拟议的药理学策略.
主要成果:
- 最近的临床试验表明,在HFmrEF/HFpEF中,费内伦和类似葡萄糖的-1受体激动剂的结果很有希望.
- 这些药物显示出超越传统疗法的疾病修饰潜力.
- 有证据表明,这些药物可以改善HFmrEF/HFpEF患者的临床结果.
结论:
- 芬和GLP-1受体激动剂代表了HFmrEF/HFpEF药物治疗的新前沿.
- 为改善患者护理,建议采用包含这些药物的更新药理策略.
- 这些进展为更好地管理心力衰竭提供了希望,通过保留和轻微减少射出分数来改善心力衰竭.
更多相关视频
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.4K
07:24Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.2K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
363
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363
01:22Heart Failure Drugs: Diuretics
324
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
324
01:22Heart Failure Drugs: β-Blockers
306
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
306
01:26Heart Failure Drugs: Inotropic Agents
495
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
495
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:33Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K